TetraLogic Pharmaceuticals Corporation
TLOG
$0.00
$0.000.00%
OTC PK
| 09/30/2016 | 06/30/2016 | 03/31/2016 | 12/31/2015 | 09/30/2015 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -41.69% | -17.39% | -5.22% | -8.39% | -3.83% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -83.38% | -63.37% | -34.53% | 6.40% | 0.32% |
| Operating Income | 83.38% | 63.37% | 34.53% | -6.40% | -0.32% |
| Income Before Tax | -0.51% | 43.18% | 12.75% | -19.53% | -16.78% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 20.76% | 43.18% | 12.75% | -19.53% | -16.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 20.76% | 43.18% | 12.75% | -19.53% | -16.78% |
| EBIT | 83.38% | 63.37% | 34.53% | -6.40% | -0.32% |
| EBITDA | 83.39% | 63.41% | 34.99% | -6.36% | -0.16% |
| EPS Basic | 23.75% | 46.47% | 19.64% | -7.64% | -9.30% |
| Normalized Basic EPS | 68.90% | 51.02% | 33.21% | 11.82% | -9.62% |
| EPS Diluted | 23.53% | 46.94% | 19.11% | -7.64% | -8.02% |
| Normalized Diluted EPS | 68.86% | 50.94% | 33.10% | 11.82% | -9.73% |
| Average Basic Shares Outstanding | 3.94% | 6.16% | 8.57% | 11.03% | 6.83% |
| Average Diluted Shares Outstanding | 3.79% | 5.99% | 8.36% | 11.03% | 6.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |